drugset / Trial / NCT06425900

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

NCT06425900

Phase 4 Active not recruiting 10 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

to compare facial sebaceous gland morphology after 3 months of clascoterone cream 1% treatment and to compare facial sebum constituents at baseline to facial sebum constituents after 3 months of clascoterone cream 1% treatment

Timeline

Start
2024-07-01
Primary completion
2026-03
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clascoterone Small molecule 1 %

Indications